RME Hot Seat: Weighing the Clinical Evidence on Treatment Strategies for Myeloma

Jointly provided by

MMRF logo    

Support for this activity has been provided through educational grants from Adaptive Biotechnologies Corporation; Amgen, Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics, Inc.; and Oncopeptides.

The joint sponsors also wish to thank CURE and Targeted Oncology for their support.

Release date: 4/16/2021

Expiration date: 4/16/2022

Estimated time to complete: 0.5 hour

Overview

This RME Hot Seat provides a virtual Q&A with a panel of multiple myeloma (MM) experts who field a range of questions on MM patient care, covering such topics as the use of minimal residual disease (MRD)–driven maintenance approaches, immunotherapy, the use of belantamab mafodotin, cytogenetic risk status, and the value of three-drug and four-drug regimens.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with MM.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate emerging data regarding the approach to maintenance therapy based on MRD status
  • Describe the options available to patients who have relapsed from or are resistant to multiple prior therapies
  • Incorporate the use of novel agent/monoclonal antibody–based regimens for newly diagnosed or relapsed/refractory MM patients based on currently available evidence

Faculty

Hearn Jay Cho, MD, PhD
Chief Medical Officer
Multiple Myeloma Research Foundation
Norwalk, Connecticut
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Adam D. Cohen, MD
Associate Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Suzanne Lentzsch, MD, PhD
Professor of Medicine
College of Physicians and Surgeons
Columbia University Medical Center
Director, Multiple Myeloma and Amyloidosis Service
New York Presbyterian Hospital/Columbia University Medical Center
New York, New York

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

In accordance with the ACCME Standards for Integrity and Independence, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 24 months with an ineligible company whose products or services are discussed in the CME activity content over which the individual has control.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures are as follows:

Faculty
Hearn Jay Cho, MD, PhD, has disclosed the following relevant financial relationships:
Research Grant: Bristol Myers Squibb/Celgene, Takeda  

Adam D. Cohen, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: AstraZeneca, Bristol Myers Squibb/Celgene, Genentech, GlaxoSmithKline, Janssen, Seattle Genetics, Takeda
Research Grant: Novartis
Royalties/Patents: Novartis  

Suzanne Lentzsch, MD, PhD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Caelum Bioscience, Celularity, Janssen, Sorrento
Research Grant: Karyopharm, Sanofi                      
Royalties/Patents: Caelum Bioscience  
Stock Ownership: Caelum Bioscience

Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Multiple Myeloma Research Foundation
Mary DeRome, Director of Medical Communications and Education, has disclosed no relevant financial relationships.

RedMedEd
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Kristen Petro Slade, Director of Operations, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.
Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Adaptive Biotechnologies Corporation; Amgen, Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics, Inc.;  Oncopeptides; CURE; and Targeted Oncology do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Adaptive Biotechnologies Corporation; Amgen, Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics, Inc.; Oncopeptides; CURE; or Targeted Oncology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 75% or greater) and program evaluation. Certificates can be printed immediately.

For questions regarding CME credit, please contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6702-21-T.

For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or education@redmeded.com.

Hardware/Software Requirements

  • Apple iPad, iPad Mini (iOS 11 or higher), iPhones (iOS 11 or higher), and Android phones (4.0.3 or higher) with an Internet connection
    • Internet browsers: Chrome, Firefox, Safari
  • A computer with an Internet connection
    • Internet browsers (PC): Chrome, Firefox, Microsoft Edge, and Internet Explorer 11 or higher.
    • Internet browsers (Mac): Chrome, Firefox, and Safari 13 or higher

Privacy Policy

CME credit for this activity is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Penn State College of Medicine so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. Penn State College of Medicine or RedMedEd may use the information you provide on this site to contact you about your CME credit or other relevant educational activities. For more information, contact ContinuingEd@hmc.psu.edu or education@redmeded.com.

Copyright

© 2021. This CME-certified program is held as copyrighted by Penn State College of Medicine, MMRF, and RedMedEd. Through this notice, Penn State College of Medicine, MMRF, and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.